Foamix To File For Wall Street IPO

August 17, 2014 | An Israeli company developing foam-based drugs for skin diseases, Foamix, has published a draft prospectus for raising up to $75 million on Wall Street. The company is set to be valued at $100-$200 million, after money with investment banks Oppenheimer and Maxim leading the offering. Foamix was founded in 2003 by CEO Dov Tamarkin and chairman and COO Meir Eini, both of whom where previously the founders of medical equipment companies.